Listen to our Editorial Board reflecting on their highlights from the ADA scientific sessions, with discussion on the VERTIS-CV trial, diets for diabetes, insulin icodec and more (34:17).
Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.
Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes [read more].
Nephrologist and Endocrinologist Katherine Tuttle joins Primary Care Physician Jay Shubrook to discuss the importance of kidney disease screening for the prevention of downstream nephropathy and cardiovascular disease in patients with diabetes [watch the video 8:16].
The authors examine the association between protein intake and type 2 diabetes mellitus in different dietary patterns [read more]. Ke Q et al. Diabetol Metab Syndr 2018; 10: 48. doi: 10.1186/s13098-018-0350-5
This review will evaluate mechanisms responsible for chronic kidney disease-induced insulin resistance and therapies currently available [read more]. Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8
We present one successful case that demonstrates a significantly beneficial effect of physical exercise and lifestyle intervention in the management of type 2 diabetes mellitus [read more]. Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7
Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.
A systematic review and meta-analysis of randomized controlled trials was conducted to quantitatively synthesize existing scientific evidence on the glycemic impact of non-nutritive sweeteners [read more]. Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6
We estimate the risk of developing long-term major cardiovascular and renal complications in relation to levels of body mass index in a population of White European, African-Caribbean, and South Asian patients with type 2 diabetes mellitus [read more]. Owusu Adjah ES et al. Cardiovasc Diabetol 2018; 17: 70. doi: 10.1186/s12933-018-0712-1
An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
